NCCR TransCure (2010–2022)
NCCR Directors: Matthias Hediger (2010–2014), Hugues Abriel (2015–2022)
Home institution: University of Berne
Research of the NCCR
The NCCR “TransCure – From Transport Physiology to Identification of Therapeutic Targets” combined the disciplines of physiology, structural biology and chemistry to develop new therapeutic strategies for treating diseases linked to malfunctions of proteins that are involved in transporting molecules in the human body. These diseases include diabetes, high blood pressure, osteoporosis, heart diseases and certain types of cancer. By broadening scientific knowledge of how transport proteins work, the NCCR applied a fundamental research approach but kept a disease-oriented perspective.
Scientific impact
The integration of leading researchers from the three disciplines into a single entity has proven particularly successful and led to ground-breaking results in the structural and mechanistic understanding of numerous transport proteins. The NCCR gained attention as an internationally leading consortium that positioned Swiss research as a major actor in membrane transport biology, the subfield of biology concerned with cellular transport proteins. In particular, the Institute of Biochemistry and Molecular Medicine at the University of Bern, the NCCR’s home institution, has gained international visibility for membrane biology in Switzerland.
Legacy
During its lifetime, the NCCR continuously examined the translational potential of its ongoing projects, which ultimately led to the founding of the start-up company Synendos Therapeutics. In addition, the NCCR TransCure contributed to the development of key infrastructure, for instance by creating the Screening, Profiling and Analytical Facility (SPAF), which provides valuable services for preclinical drug development. To continuously support their scientific communities, the two NCCRs TransCure and Kidney.CH joined forces to establish the new “Ion Channels and Membrane Transporters” section of Life Sciences Switzerland (LS2). This initiative is expected to maintain the current TransCure network and provide a basis for new collaborations with research groups outside the NCCR.
Funding
The SNSF awarded 33.5 million Swiss francs to the NCCR over a duration of 12 years. The table below shows that this amount represents just over 41 percent of the NCCR’s overall expenditures. The remaining funds were either own funds provided by the home institution or the participating groups, or contributions by third parties.
Financing 2010–2022 (Swiss francs)
Funding source
2010-2014
2014-2018
2018-2022
Overall
SNSF grant
14,042,664
11,587,163
7,916,809
33,546,636
Funds from the home institution
4,590,667
4,349,751
4,674,747
13,615,165
Group funds of the project participants
12,705,603
11,308,915
8,685,452
32,699,970
External funds
0
656,305
568,706
1,225,011
Total
31,338,934
27,902,134
21,845,713
81,086,782
Source: SNSF data